research Combination use of triamcinolone acetonide and immunotherapy as a new therapeutic option in alopecia totalis
Combining triamcinolone acetonide and immunotherapy can help regrow hair in some alopecia totalis patients.
Search
for
Sort by
Research
570-600 / 1000+ results research Hereditary 1,25-dihydroxyvitamin D-resistant rickets with alopecia in four Egyptian families: report of three novel mutations in the vitamin D receptor gene
Three new gene mutations cause rickets and hair loss, treatable with high calcium and calcidol, but hair regrowth is rare.
research A Retrospective Comparative Study of Two Concentrations of Intralesional Triamcinolone Acetonide in the Treatment of Patchy Alopecia Areata on the Scalp
Both concentrations of triamcinolone acetonide are equally effective and safe for treating patchy alopecia areata.
research Differential activity of 2-methylene-19-nor vitamin D analogs on growth factor gene expression in rhino mouse skin and comparison to all-trans retinoic acid
Some vitamin D analogs can thicken skin and reduce pore size like a common acne treatment, with one analog also affecting skin growth factors.
research Novel DualSoftDrug Strategy Enables Developmentof Topical Androgen Receptor Antagonists with Enhanced Efficacy andOptimized Safety for Androgenetic Alopecia
A new topical treatment for hair loss is effective and safe with faster results.
research Abiraterone and spironolactone in prostate cancer: a combination to avoid
Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.
research A Connection between the Mitochondrial Permeability Transition Pore, Autophagy, and Cerebral Amyloidogenesis
Dutasteride may help reduce brain plaque linked to Alzheimer's by affecting cell energy structures and waste removal.
research Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study
Ritlecitinib is effective and safe for long-term treatment of alopecia areata.
research Valproate‐associated hair abnormalities: Pathophysiology and management strategies
Valproate can cause hair problems, but there are ways to manage them.
research IN VITRO HIV-1 REVERSE TRANSCRIPTASE INHIBITION BY ALKALOIDS ISOLATED FROM LEAVES OF ECLIPTA ALBA
Eclipta alba leaf alkaloids may help treat HIV by inhibiting the virus's activity.
research Evaluation of 5α-reductase inhibitory activity of certain herbs useful as antiandrogens
Some herbs show promise as antiandrogenic agents.
research 320 An open label clinical trial of Abatacept (CTLA4-Ig) for alopecia areata
Abatacept may help some people with alopecia areata regrow hair.
research FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
Deuruxolitinib is FDA-approved for treating severe alopecia areata.
research Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
Upadacitinib effectively treats severe alopecia areata and is safe.
research Metabolic and Vascular Inflammation in Alopecia Areata: Linking Uric Acid, Lipid Imbalance and ICAM ‐1 Upregulation
Improving blood vessel health and controlling uric acid may help manage alopecia areata.
research The Role of PPARβ/δ-Related Lipid Metabolism in High-Altitude Adaptation of Yak Coat Based on Proteomics and Metabolomics
PPARβ/δ helps yaks adapt to high altitudes by regulating lipid metabolism in their coats.
research ISIDLB1680 - Effects of Ganoderma Lucidum extract and its active component, ganoderic acid A on hair loss prevention
Ganoderma Lucidum extract and ganoderic acid A can help prevent hair loss.
research Safety and Efficacy of Ritlecitinib for the Treatment of Patients with Alopecia Areata: A Systematic Review and Meta-Analysis of Controlled Trials
Ritlecitinib effectively treats alopecia areata with manageable side effects.
research Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
research Serum Biotinidase Activity in Children Treated With Valproic Acid and Carbamazepine
Valproic acid does not change biotinidase enzyme activity in children's blood.
research Structural characterization and bioactive screening of two homogeneity proteins from Tianshan red deer abomasum
Proteins from Tianshan red deer abomasum have strong anti-inflammatory, anti-tumor, and antioxidant effects.
research Identifying the Active Components and Mechanisms of Persicae Semen in Treating Androgenetic Alopecia: Insights from Network Pharmacology and Experimental Evaluations
Amygdalin in Persicae Semen may help treat hair loss by promoting hair growth and regulating key pathways.
research Study of association between valproic acid levels, biotinidase activity and hair loss in Indian population: A cross-sectional comparative study
Valproic acid treatment may cause hair loss due to reduced biotinidase activity.
research Topical Finasteride Therapy in Hirsutism
Topical finasteride may help treat facial hirsutism in women.
research Analytical methods of dutasteride: An overview
Dutasteride is more effective than finasteride for hair loss treatment.
research Adverse reaction to isotretinoin: alteration of the hair shaft structure
Isotretinoin can rarely cause hair to grow curly.
research Neuropharmacological profile of Eclipta alba (Linn.) Hassk
Eclipta alba extract improved learning, memory, and stress-related ulcers in rats without affecting movement or causing anxiety.
research Involvement of neurosteroids in the anxiolytic-like effects of AC-5216 in mice
AC-5216 reduces anxiety in mice through neurosteroids affecting GABAA receptors.
research Treatment of acne with intermittent isotretinoin, cohort study
Intermittent isotretinoin can cause various skin, hair, and nail changes.
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.